Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Crestor RUSH (The Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension )

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: September 5, 2007
Last updated: November 30, 2010
Last verified: November 2010

To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with hypertension.


Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: RUSH (Evaluating the Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension in Real World Practice)

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Estimated Enrollment: 5000
Study Start Date: May 2007
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Hypertensive hypercholesteromia patients in Korean tertiary care centers


Inclusion Criteria:

  • Hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on clinical grounds and fulfil the following criteria

    1. Over 18 years of age
    2. Currently or previously diagnosed with hypertension and receiving medical care

Exclusion Criteria:

  1. Patients already taking other hyperlipidemic agents
  2. Patients who do not fulfil the indication criteria for statin therapy
  3. Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00526708

Korea, Republic of
Research Site
Seoul, Jongro-gu, Korea, Republic of
Research Site
Seoul, Kangnam-gu, Korea, Republic of
Research Site
Seoul, Songpa-gu, Korea, Republic of
Sponsors and Collaborators
Study Director: Hyunah Caroline Choi AstraZeneca Korea
  More Information

No publications provided Identifier: NCT00526708     History of Changes
Other Study ID Numbers: NIS-CKR-CRE-2007/2
Study First Received: September 5, 2007
Last Updated: November 30, 2010
Health Authority: Korea: Food and Drug Administration

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Cardiovascular Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Vascular Diseases
Anticholesteremic Agents
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on March 03, 2015